TAK1: a Potent Tumour Necrosis Factor Inhibitor for the Treatment of Inflammatory Diseases

Overview

Journal Open Biol

Specialties Biology
Cell Biology
Molecular Biology

Date 2020 Sep 3

PMID 32873150

Citations 19

Authors

Juliane Totzke

Scott A Scarneo

Kelly W Yang

Timothy A J Haystead

Affiliations

Soon will be listed here.

Abstract

Aberrant tumour necrosis factor (TNF) signalling is a hallmark of many inflammatory diseases including rheumatoid arthritis (RA), irritable bowel disease and lupus. Maladaptive TNF signalling can lead to hyper active downstream nuclear factor (NF)-κβ signalling in turn amplifying a cell's inflammatory response and exacerbating disease. Within the TNF intracellular inflammatory signalling cascade, transforming growth factor-β-activated kinase 1 (TAK1) has been shown to play a critical role in mediating signal transduction and downstream NF-κβ activation. Owing to its role in TNF inflammatory signalling, TAK1 has become a potential therapeutic target for the treatment of inflammatory diseases such as RA. This review highlights the current development of targeting the TNF-TAK1 signalling axis as a novel therapeutic strategy for the treatment of inflammatory diseases.

Citing Articles

Critical Analysis of Cytoplasmic Progression of Inflammatory Signaling Suggests Potential Pharmacologic Targets for Wound Healing and Fibrotic Disorders.

Samulevich M, Carman L, Aneskievich B Biomedicines. 2025; 12(12.

PMID: 39767629 PMC: 11726985. DOI: 10.3390/biomedicines12122723.

Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical Models.

Freeze R, Hughes P, Haystead T, Scarneo S J Pain Res. 2024; 17:2287-2298.

PMID: 38952995 PMC: 11216608. DOI: 10.2147/JPR.S451409.

Disruption of TIGAR-TAK1 alleviates immunopathology in a murine model of sepsis.

Wang D, Li Y, Yang H, Shen X, Shi X, Li C Nat Commun. 2024; 15(1):4340.

PMID: 38773142 PMC: 11109194. DOI: 10.1038/s41467-024-48708-0.

TAK1 inhibition mitigates intracerebral hemorrhage-induced brain injury through reduction of oxidative stress and neuronal pyroptosis via the NRF2 signaling pathway.

Zhao J, Chen C, Ge L, Jiang Z, Hu Z, Yin L Front Immunol. 2024; 15:1386780.

PMID: 38756773 PMC: 11096530. DOI: 10.3389/fimmu.2024.1386780.

TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers.

Damhofer H, Tatar T, Southgate B, Scarneo S, Agger K, Shlyueva D Cell Death Dis. 2024; 15(4):273.

PMID: 38632238 PMC: 11024179. DOI: 10.1038/s41419-024-06654-1.

References

Muller J, Ory S, Copeland T, Piwnica-Worms H, Morrison D . C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. Mol Cell. 2001; 8(5):983-93. DOI: 10.1016/s1097-2765(01)00383-5. View

Hornef M, Henriques Normark B, Vandewalle A, Normark S . Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med. 2003; 198(8):1225-35. PMC: 2194240. DOI: 10.1084/jem.20022194. View

Pap T, Korb-Pap A . Cartilage damage in osteoarthritis and rheumatoid arthritis--two unequal siblings. Nat Rev Rheumatol. 2015; 11(10):606-15. DOI: 10.1038/nrrheum.2015.95. View

Kilty I, Jones L . TAK1 selective inhibition: state of the art and future opportunities. Future Med Chem. 2015; 7(1):23-33. DOI: 10.4155/fmc.14.138. View

Geng J, Ito Y, Shi L, Amin P, Chu J, Ouchida A . Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. Nat Commun. 2017; 8(1):359. PMC: 5572456. DOI: 10.1038/s41467-017-00406-w. View

Okada Y, Raj T, Yamamoto K . Ethnically shared and heterogeneous impacts of molecular pathways suggested by the genome-wide meta-analysis of rheumatoid arthritis. Rheumatology (Oxford). 2015; 55(1):186-9. DOI: 10.1093/rheumatology/kev314. View

Hornberger K, Chen X, Crew A, Kleinberg A, Ma L, Mulvihill M . Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics. Bioorg Med Chem Lett. 2013; 23(16):4511-6. DOI: 10.1016/j.bmcl.2013.06.054. View

Liu Z, Kong F, Vallance J, Harmel-Laws E, Amarachintha S, Steinbrecher K . Activation of TGF- activated kinase 1 promotes colon mucosal pathogenesis in inflammatory bowel disease. Physiol Rep. 2017; 5(7). PMC: 5392505. DOI: 10.14814/phy2.13181. View

Sporn M, Roberts A . TGF-beta: problems and prospects. Cell Regul. 1990; 1(12):875-82. PMC: 362858. DOI: 10.1091/mbc.1.12.875. View

10.

Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N . The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol. 2008; 10(10):1199-207. DOI: 10.1038/ncb1780. View

11.

Onuora S . Rheumatoid arthritis: JAK-ing up inadequate RA therapy. Nat Rev Rheumatol. 2017; 13(9):513. DOI: 10.1038/nrrheum.2017.114. View

12.

Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F . TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010; 17(5):481-96. DOI: 10.1016/j.ccr.2010.03.021. View

13.

Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T . The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002; 41(3):329-37. DOI: 10.1093/rheumatology/41.3.329. View

14.

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

15.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

16.

Le Goff C, Rogers C, Le Goff W, Pinto G, Bonnet D, Chrabieh M . Heterozygous Mutations in MAP3K7, Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome. Am J Hum Genet. 2016; 99(2):407-13. PMC: 4974068. DOI: 10.1016/j.ajhg.2016.06.005. View

17.

Singh A, Umar S, Riegsecker S, Chourasia M, Ahmed S . Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6. Arthritis Rheumatol. 2015; 68(2):347-58. PMC: 5383419. DOI: 10.1002/art.39447. View

18.

Tan L, Gurbani D, Weisberg E, Jones D, Rao S, Singer W . Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem. 2017; 25(4):1320-1328. PMC: 5484535. DOI: 10.1016/j.bmc.2016.11.034. View

19.

Shim J, Xiao C, Paschal A, Bailey S, Rao P, Hayden M . TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 2005; 19(22):2668-81. PMC: 1283960. DOI: 10.1101/gad.1360605. View

20.

Totzke J, Gurbani D, Raphemot R, Hughes P, Bodoor K, Carlson D . Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chem Biol. 2017; 24(8):1029-1039.e7. PMC: 5576570. DOI: 10.1016/j.chembiol.2017.07.011. View